• There are no suggestions because the search field is empty.
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update
November 11, 2020
Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
November 11, 2020
Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast
October 23, 2020
Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19
October 21, 2020
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy
October 19, 2020
Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020
October 19, 2020
Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020
October 19, 2020
Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination
October 16, 2020
Beyond Air® to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy
September 30, 2020
Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit
September 11, 2020

Sign up for updates from Beyond Air, Inc.